Despite a theoretical rationale and profound preclinical proof of HDACi efficacy in myeloid malignancies, all phase II randomized clinical trials have failed, except for the combination of HDACi with JAK2 inhibitor ruxolitinib in MF. This evidence concerns the gene JAK2 and myeloid neoplasm.